Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Efficacy of transplantation in HL

Yago Nieto • 10 Apr 2022
AACR 2022
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin

In this video, Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the efficacy of both autologous and allogeneic stem cell transplantation (SCT) in patients with Hodgkin lymphoma (HL). Prof. Nieto further highlights a study which aims to induce complete response (CR) in patients and improve curability. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

More from Yago Nieto

2:10
High-dose chemotherapy and autoSCT for R/R primary mediastinal large B-cell lymphoma
Yago Nieto • 11 Dec 2023
2:55
AFM13 with cord blood-derived NK-cell therapy in patients with refractory CD30-positive lymphomas
Yago Nieto • 11 Dec 2023
3:32
Phase II study of panobinostat/GemBuMel with autoSCT in high-risk or R/R multiple myeloma
Yago Nieto • 13 Feb 2023
2:33
Phase I/II study of olaparib plus vorinostat/GemBuMel with autoSCT in R/R lymphomas
Yago Nieto • 11 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals